Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target
Written by
PharmaTimes
Published
0
comments
0
min
Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection